gene bridge

gene bridge

the means by which a plant pathogen can survive between the main host-growing seasons by living on host plants grown out of the normal season. Thus, for example, a cereal pathogen can often transfer in September from a mature, spring-sown host to newly sown winter cereal plants.
References in periodicals archive ?
Gene Bridges, 595-6170; 75 homes; no printed list, but can recommend a suitable house by telephone or by mail.
HEIDELBERG, Germany -- Gene Bridges GmbH, the recombineering company, today announced that Chugai Pharmaceutical Co.
Red/ET is fast becoming the standard DNA engineering technology used in industry and academia worldwide," commented Gary Stevens, CEO of Gene Bridges GmbH.
Gene Bridges is represented in Japan by the distribution partner Funakoshi.
Recent Industry Activity II-39 International Consolidated to Acquire China Gene II-39 Ark Therapeutics to Acquire Lymphatix II-39 Oxford BioMedica Obtains Rights for RNAi Technology II-39 Gene Bridges Inks Licensing Agreement with Genencor II-39 AMT Enters into R&D Agreement with NIH II-40 VGX Inks Supply Agreement with a U.
HEIDELBERG, Germany -- Gene Bridges GmbH, the recombineering company, today announced that Novozymes has completed a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges.
Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Novozymes for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications.
Under the terms of the agreement, Gene Bridges has licensed the Red/ET technology to Genencor for the purpose of genetically engineering recombinant micro-organisms for use in industrial applications.
The commercial companies include Leica Microsystems CMS GmbH, Germany and Gene Bridges GmbH, Germany.
Gala Biotech/Cardinal Health, Galapagos Genomics, Gene Bridges GmbH, GPC Biotech AG, Health Protection Agency, Hunter-Fleming Limited, Hybridon, Inc.
De Novo Pharmaceuticals Ltd, EGeen International, Endocube, Epigenomics AG, Evotec OAI, ExonHit Therapeutics, Gala Biotech/Cardinal Health, Galapagos Genomics, Gene Bridges GmbH, Global Genomics AB, GPC Biotech AG, Health Protection Agency, Hybridon, Inc.
EGeen International, Epigenomics AG, Evotec OAI, ExonHit Therapeutics, Gala Biotech/Cardinal Health, Galapagos Genomics, Gene Bridges GmbH, Global Genomics AB, GPC Biotech AG, Graffinity Pharmaceuticals, Health Protection Agency, Inex Pharmaceuticals Corporation, Inflazyme Pharmaceuticals, Ingenium Pharmaceuticals AG, Inimex Pharmaceuticals Inc.